Evidence map›Paper›PMID 37999120›Full record

ReviewCurrent oncology (Toronto, Ont.)2023

Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective.

Don Husereau, Yvonne Bombard, Tracy Stockley, Michael Carter, Scott Davey, Diana Lemaire, Erik Nohr, Paul Park, Alan Spatz, Christine Williams and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Translating evidence into practice: Developing Canada's first position statement on genomics-informed oncology nursing.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2026
    Article
  4. Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 1 country.

Don HusereauSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.ORCID 0000-0002-4416-6876
Yvonne BombardInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada.
Tracy StockleyDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada.ORCID 0000-0002-4476-9722
Michael CarterDepartment of Pathology and Laboratory Medicine, Nova Scotia Health (Central Zone), Halifax, NS B3H 1V8, Canada.ORCID 0000-0003-3964-9790
Scott DaveyDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Diana LemaireOntario Institute for Cancer Research, 661 University Ave, Toronto, ON M5G 0A3, Canada.
Erik NohrDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0001-5646-6940
Paul ParkDepartment of Pathology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.
Alan SpatzDivision of Pathology, McGill University Health Center, 1001 Decarie Blvd., Montreal, QC H4A 3J, Canada.ORCID 0000-0003-3020-1420
Christine WilliamsDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Aaron PollettPathology & Laboratory Medicine, Sinai Health System, Toronto, ON M5G 1X5, Canada.ORCID 0000-0001-5121-8788
Bryan LoThe Ottawa General Hospital, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
Stephen YipDepartment of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.ORCID 0000-0002-8514-9861
Soufiane El HallaniAlberta Precision Laboratory, Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.ORCID 0009-0009-8414-4151
Harriet FeilotterDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0002-1388-2183
Ontario Institute for Cancer Research · CAMcGill University Health Centre · CANova Scotia Health Authority · CAOttawa Hospital · CAQueen's University · CASt. Michael's Hospital · CAUniversity Health Network · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Manitoba · CAUniversity of Ottawa · CAUniversity of Toronto · CA

Funding

Canadian Cancer Society 1001
6 · The paper itself

Abstract

Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment, and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology.

Indexed as

Genomic MedicineTechnology Assessment, BiomedicalCanadaGenomicsHumansMedical Oncologyanalytic validityclinical utilityclinical validitygenomic biomarkershealth technology assessment

Identifiers

PMID37999120
PMCPMC10670221
OpenAlexW4388076903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.